disopyramide has been researched along with Myocardial Ischemia in 9 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine whether a quantitative relation exists between changes in regional myocardial blood flow (RMBF) and those in electrophysiologic determinants recorded via left ventricular endocardial and epicardial bipolar electrograms after administration of disopyramide (DP) and a class III antiarrhythmic drug, MS-551 (MS), during myocardial ischemia in the dog." | 7.70 | Electrophysiologic and blood-flow responses in the endocardium and epicardium to disopyramide and MS-551 during myocardial ischemia in the dog. ( Aikawa, M; Handa, S; Iwamoto, T; Iwata, O; Kusuzaki, S; Mori, H; Shinozaki, Y; Tanabe, T, 1999) |
| "We investigated the effects of (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate (Ro 22-9194), a novel class I antiarrhythmic agent, on myocardial ischemia- and reperfusion-induced arrhythmias in dogs." | 7.69 | Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act ( Kanazawa, T; Kinukawa, M; Maruyama, K; Miyagi, M; Miyata, H; Murakami, M; Ujiie, A, 1996) |
| "The aim of this study was to determine whether a quantitative relation exists between changes in regional myocardial blood flow (RMBF) and those in electrophysiologic determinants recorded via left ventricular endocardial and epicardial bipolar electrograms after administration of disopyramide (DP) and a class III antiarrhythmic drug, MS-551 (MS), during myocardial ischemia in the dog." | 3.70 | Electrophysiologic and blood-flow responses in the endocardium and epicardium to disopyramide and MS-551 during myocardial ischemia in the dog. ( Aikawa, M; Handa, S; Iwamoto, T; Iwata, O; Kusuzaki, S; Mori, H; Shinozaki, Y; Tanabe, T, 1999) |
| "We investigated the effects of (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate (Ro 22-9194), a novel class I antiarrhythmic agent, on myocardial ischemia- and reperfusion-induced arrhythmias in dogs." | 3.69 | Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act ( Kanazawa, T; Kinukawa, M; Maruyama, K; Miyagi, M; Miyata, H; Murakami, M; Ujiie, A, 1996) |
| "Drug treatment of hypertrophic cardiomyopathy is the first-line treatment, at the onset of clinical signs and symptoms." | 1.35 | [Drug treatment for hypertrophic cardiomyopathy]. ( Gibelin, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gibelin, P | 1 |
| Eleftheriadis, D | 1 |
| Panagiotis, V | 1 |
| Eleftheriadis, N | 1 |
| Komori, S | 1 |
| Sawanobori, T | 1 |
| Tamura, K | 1 |
| Kane, KA | 1 |
| Parratt, JR | 1 |
| de Lorenzi, FG | 1 |
| Bridal, TR | 1 |
| Spinelli, W | 1 |
| Murakami, M | 1 |
| Kinukawa, M | 1 |
| Kanazawa, T | 1 |
| Maruyama, K | 1 |
| Miyagi, M | 1 |
| Miyata, H | 1 |
| Ujiie, A | 1 |
| Aupetit, JF | 1 |
| Loufoua-Moundanga, J | 1 |
| Faucon, G | 1 |
| Timour, Q | 1 |
| Tanabe, T | 1 |
| Iwamoto, T | 1 |
| Iwata, O | 1 |
| Aikawa, M | 1 |
| Kusuzaki, S | 1 |
| Handa, S | 1 |
| Shinozaki, Y | 1 |
| Mori, H | 1 |
| Sakai, Y | 1 |
| Hayashi, Y | 1 |
| Tomobuchi, Y | 1 |
| Hano, T | 1 |
| Nishio, I | 1 |
| Nikitin, AV | 1 |
| Zemskov, AM | 1 |
| Zemskov, VM | 1 |
| Gusmanov, VA | 1 |
| Evstratova, EF | 1 |
9 other studies available for disopyramide and Myocardial Ischemia
| Article | Year |
|---|---|
[Drug treatment for hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiomyop | 2009 |
Recurrent syncopic episodes as a consequence of combined Brugada syndrome and paroxysmal atrial fibrillation. Which is the therapy of choice?
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Disopyramide; Female; Humans | 2004 |
Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
Topics: Amino Alcohols; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Dise | 1994 |
Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Cats; Disopyramide; Dose-Response Relationship, | 1995 |
Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cyclooxygenase | 1996 |
Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Vessels; Disopyramide; Electric Stimulatio | 1997 |
Electrophysiologic and blood-flow responses in the endocardium and epicardium to disopyramide and MS-551 during myocardial ischemia in the dog.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Circulation; Disopyramide; Dogs; Endocardi | 1999 |
Dynamic outflow obstruction due to the transient extensive left ventricular wall motion abnormalities caused by acute myocarditis in a patient with hypertrophic cardiomyopathy: reduction in ventricular afterload by disopyramide.
Topics: Acute Disease; Aged; Cardiomyopathy, Hypertrophic; Coronary Angiography; Disopyramide; Echocardiogra | 1999 |
[The clinico-immunological aspects of ventricular extrasystole in ischemic heart disease].
Topics: Adjuvants, Immunologic; Antibody Formation; Cardiac Complexes, Premature; Disopyramide; Electrocardi | 1992 |